This Frontiers in Allergy editorial synthesises challenges in house-dust-mite allergy across avoidance, medication, immunotherapy, biologics and environmental exposure. It emphasises patient and geographic heterogeneity and a move toward precision care. It is not a systematic review, clinical guideline or new treatment trial.
Key findings
- The editorial cites an estimated 65–130 million affected globally and sensitisation above 50% in some mite-rich allergic populations. Avoidance alone is often insufficient; treatment selection should consider phenotype, exposure, severity, comorbidity and resources.
Why this matters globally
The multilevel framing is relevant to mite-rich tropical settings and supports research on biomarkers, exposure measurement and comparative effectiveness that includes cost and equity.
Thai researcher contribution
Pongsakorn Tantilipikorn of Siriraj Hospital, Mahidol University, co-edited the international topic, representing Thai expertise in tropical allergy and evidence-to-research translation.
Limitations to consider
As an editorial, burden estimates depend on cited sources and population definitions. It does not directly compare treatment effectiveness or safety and must not replace individual medical advice.